Key result
Anti-GPIIb/IIIa and anti-GPIbα antibodies inhibit platelet-dependent thrombin generation via distinct mechanisms.
Why the study?
The antithrombotic effect of antiplatelet agents involves anti-aggregatory action and potential interference with coagulation, but the mechanisms by which monoclonal antibodies against platelet glycoproteins affect thrombin generation are unclear.
Monoclonal antibodies against platelet glycoproteins IIb/IIIa and Ibα inhibit platelet-dependent thrombin generation through distinct mechanisms related to procoagulant phospholipid exposure.
Supports dual antithrombotic mechanisms for GPIIb/IIIa blockade; leaves open in vivo relevance and clinical translation.
The antithrombotic effect of antiplatelet agents is principally due to their anti-aggregatory action, but these agents may also interfere with coagulation. We have investigated the effect of monoclonal antibodies (MAb) to platelet membrane glycoproteins (GP) IIb/IIIa and Ibalpha on thrombin generation. Antibodies to platelet membrane glycoprotein IIb/IIIa (RFGP56 and c7E3) were shown to inhibit platelet-mediated thrombin generation stimulated by both intrinsic and extrinsic methods. An antibody to GP Ibalpha (RFGP37) also inhibited thrombin generation in these systems. FITC-annexin V was used to determine the effect of these antibodies on the exposure of procoagulant phospholipids on the platelet membrane, and it was found that the anti-IIb/IIIa antibodies reduced this, whereas the anti-Ibalpha antibody caused an increase. We conclude that our monoclonal antibodies against platelet membrane glycoproteins IIb/IIIa and Ibalpha inhibit platelet dependent thrombin generation by different mechanisms.
No takes yet. Share an insight, caveat, or question.
A 2000 study studied this question. Monoclonal antibodies to platelet membrane glycoproteins IIb/IIIa and Ibalpha was evaluated on Platelet-mediated thrombin generation and exposure of procoagulant phospholipids. Monoclonal antibodies against platelet membrane glycoproteins IIb/IIIa and Ibalpha inhibited platelet-dependent thrombin generation by different mechanisms.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: